PDF herunterladen
Der Klinikarzt 2014; 43(S 01): 48-52
DOI: 10.1055/s-0034-1377056
Schwerpunkt
© Georg Thieme Verlag Stuttgart · New York

Vorhofflimmerablation und Antikoagulation – Welches Patientenkollektiv kann profitieren?

Atrial fibrillation and anticoagulation – Which patients might benefit most?
Bernd-Dieter Gonska
1   St. Vincentius-Kliniken Karlsruhe, Medizinische Klinik III, Kardiologie, Intensivmedizin, Angiologie, Akademisches Lehrkrankenhaus der Universität Freiburg
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
07. Mai 2014 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

Die Antikoagulation bei Vorhofflimmern richtet sich nach dem CHA2DS2-VASc-Score. Nach einer Katheterablation ist die Antikoagulation abhängig von dem vorbestehenden CHA2DS2-VASc-Score. Für die orale Antikoagulation stehen ausschließlich die Coumadine und die Direkten Oralen Antikoagulantien zur Verfügung. Die Ablation ist mit einer hohen Erfolgsrate bei symptomatischen Patienten mit paroxysmalem Vorhofflimmern durchführbar.

Summary

Anticoagulation after catheter ablation of atrial fibrillation is depending on the preexisting CHA2DS2-VASc-Score. Only Coumadines and DOACs (Direct Oral Anticoagulants) should be administered in patients with atrial fibrillation. Due to the guidelines catheter ablation is prooving to be effective in symptomatic patients with paroxysmal atrial fibrillation.

Key words

Catheter ablation - anticoagulation - Coumadin - DOAK
 

  • Literatur

  • 1 Sorgente A, Chierchia GB, de Asmundis C et al. Complications of atrial fibrillation ablation: when prevention is better than cure. Europace 2011; 13: 1526-1532
    CrossrefPubMedGoogle Scholar
  • 2 Winkle RA, Mead RH, Engel G, Patrawala RA. Long term results of atrial fibrillation ablation: The importance of all initial ablation failures undergoing a repeat ablation. Am Heart J 2011; 162: 193-200
    CrossrefPubMedGoogle Scholar
  • 3 Lip GY, Nieuwlaat R, Pisters R et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor based approach: The Euro Heart Survey on Atrial Fibrillation. Chest 2010; 137: 263-272
    CrossrefPubMedGoogle Scholar
  • 4 Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation. Eur Heart J 2012; 33: 2719-2747
    CrossrefPubMedGoogle Scholar
  • 5 Calkins H, Kuck KH, Cappato R et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow up, definitions, endpoints, and research trial design. Europace 2012; 14: 1385-1385
    CrossrefPubMedGoogle Scholar
  • 6 Calkins H, Brugada J, Packer DL et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for personnel, policy, procedures and follow-up. Heart Rhythm 2007; 4: 1-1
    CrossrefPubMedGoogle Scholar
  • 7 Camm AJ et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Europace 2012; 14: 1385-1413
    CrossrefPubMedGoogle Scholar
  • 8 Wann LS, Curtis AB, January CT et al. 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline) A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Heart Rhythm 2011; 8: 157-176
    CrossrefPubMedGoogle Scholar
  • 9 Verma A, Macle L, Cox J et al. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: catheter ablation for atrial fibrillation/flutter. Can J Cardiol 2011; 27: 60-66
    CrossrefPubMedGoogle Scholar
  • 10 Marrouche NF, Wilber D, Hindricks G et al. Association of Atrial Tissue Fibrosis Identified by Delayed Enhancement MRI and Atrial Fibrillation Catheter Ablation. The DECAAF Study. JAMA 2014; 311: 498-506
    CrossrefPubMedGoogle Scholar
  • 11 Page SP, Siddiqui MS, Finlay M et al. Catheter ablation for atrial fibrillation on uninterrupted warfarin: can it be done without echo guidance?. J Cardiovasc Electrophysiol 2011; 22: 265-270
    CrossrefPubMedGoogle Scholar
  • 12 Packer DL et al. HRS CABANA Investigators Meeting. 2013;
    PubMedGoogle Scholar
  • 13 Packer DL, Kowal RC, Wheelan KR et al. Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial. J Am Coll Cardiol 2013; 61: 1713-1723
    CrossrefPubMedGoogle Scholar
  • 14 Kuck K et al. GAP-AF study helps to define optimal approach to ablation/ SARA study shows ablation superior to drugs for patients with persistent AF. ESC 2013; Athens
    PubMedGoogle Scholar
  • 15 Kirchhof P, Fetsch T, Hanrath P et al. Targeted pharmacological reversal of electrical remodeling after Cardioversion – rationale and design of the Flecainide Short-Long (Flec-SL) trial. Am Heart J 2005; 150: 899-899
    PubMedGoogle Scholar
  • 16 Stabile G, Bertaglia E, Senatore G et al. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). Eur Heart J 2006; 27: 216-221
    CrossrefPubMedGoogle Scholar
  • 17 Lakkireddy D, Reddy YM, Di Biase L et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective register. J Am Coll Cardiol 2012; 59: 1168-1174
    CrossrefPubMedGoogle Scholar
  • 18 Lloyd-Jones DM, Wang TJ, Leip EP et al. Lifetime risk for development of atrial fibrillation: The Framingham Heart Study. Circulation 2004; 110: 1042-1046
    CrossrefPubMedGoogle Scholar
  • 19 Garnock-Jones KP et al. Dabigatran etexilate. A review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Am J Cardiovasc Drugs 2011; 11: 57-72
    CrossrefPubMedGoogle Scholar
  • 20 Eitel C, Koch J, Sommer P et al. Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation. Europace 2013; 15: 1587-1593
    CrossrefPubMedGoogle Scholar
  • 21 Sorgente A, Chierchia GB, de Asmundis C et al. Complications of atrial fibrillation ablation: when prevention is better than cure. Europace 2011; 13: 1526-1532
    CrossrefPubMedGoogle Scholar
  • 22 Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Eng J Med 2009; 361: 1139-1151
    CrossrefPubMedGoogle Scholar
  • 23 Connolly SJ, Ezekowitz MD, Yusuf S et al. Newly identified events in the RE-LY® trial. N Engl J Med 2010; 363: 1875-1876
    CrossrefPubMedGoogle Scholar
  • 24 Giugliano RP, Ruff CT, Braunwald E et al. Edoxaban versus Warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-2104
    CrossrefPubMedGoogle Scholar
  • 25 Granger CB et al. Apixaban versus Warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992
    CrossrefPubMedGoogle Scholar
  • 26 Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med 2011; 365: 883-891
    CrossrefPubMedGoogle Scholar
  • 27 Themistoclakis S, Corrado A, Marchlinski FE et al. The Risk of Thromboembolism and Need for Oral Anticoagulation After Successful Atrial Fibrillation Ablation. J Am Coll Cardiol 2010; 55: 735-743
    CrossrefPubMedGoogle Scholar
  • 28 Bunch TJ et al. Patients Treated with Catheter Ablation for Atrial Fibrillation Have Long-Term Rates of Death, Stroke and Dementia Similar to Patients without Atrial Fibrillation. J Cardiovasc Electrophysiol 2011; 22: 839-845
    CrossrefPubMedGoogle Scholar
  • 29 Bunch TJ, Crandall BG, Weiss JP et al. Atrial fibrillation ablation patients have long-term stroke rates similar to patients without atrial fibrillation regardless of CADS2 score. Heart Rhythm 2013; 10: 1272-1277
    CrossrefPubMedGoogle Scholar
  • 30 Winke RA, Mead RH, Engel G et al. The use of dabigatran immediately after atrial fibrillation ablation. J Cardiovasc Electrophysiol 2012; 23: 264-268
    CrossrefPubMedGoogle Scholar
  • 31 Providência R, Albenque JP, Combes S et al. Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Heart 2014; 100: 324-335
    CrossrefPubMedGoogle Scholar
  • 32 Reddy VY, Doshi SK, Sievert H et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. Circulation 2013; 127: 720-729
    CrossrefPubMedGoogle Scholar
  • 33 Holmes DR et al. Randomized Trial of LAA Closure vs Warfarin for Stroke/ Thromboembolic Prevention in Patients with Non-valvular Atrial Fibrillation (PREVAIL). ACC 2013; San Francisco
    PubMedGoogle Scholar